| Basics |
Nektar Therapeutics
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain.
|
| IPO Date: |
May 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$764.17M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.37 | 2.58%
|
| Avg Daily Range (30 D): |
$0.93 | 3.45%
|
| Avg Daily Range (90 D): |
$0.72 | 4.78%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.46M |
| Avg Daily Volume (30 D): |
.7M |
| Avg Daily Volume (90 D): |
1.83M |
| Trade Size |
| Avg Trade Size (Sh.): |
165 |
| Avg Trade Size (Sh.) (30 D): |
76 |
| Avg Trade Size (Sh.) (90 D): |
112 |
| Institutional Trades |
| Total Inst.Trades: |
9,016 |
| Avg Inst. Trade: |
$2.69M |
| Avg Inst. Trade (30 D): |
$1.25M |
| Avg Inst. Trade (90 D): |
$1.36M |
| Avg Inst. Trade Volume: |
.01M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.92M |
| Avg Closing Trade (30 D): |
$.85M |
| Avg Closing Trade (90 D): |
$1.53M |
| Avg Closing Volume: |
15.61K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-3.33
|
$-2.95
|
$-.24
|
|
Diluted EPS
|
$-3.33
|
$-2.95
|
$-.24
|
|
Revenue
|
$ 74.93M
|
$ 11.18M
|
$ 10.46M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -122.27M
|
$ -41.59M
|
$ -50.88M
|
|
Operating Income / Loss
|
$ -100.76M
|
$ -36.23M
|
$ -44.54M
|
|
Cost of Revenue
|
$ 12.41M
|
$ M
|
$ M
|
|
Net Cash Flow
|
$ 15.05M
|
$ 4.09M
|
$ -5.36M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 09, 2025:
1:15
|
|
Aug 23, 2000:
2:1
|
|
|
|
